Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
2.320
-0.120 (-4.92%)
At close: Apr 1, 2025, 4:00 PM
2.310
-0.010 (-0.43%)
After-hours: Apr 1, 2025, 4:41 PM EDT

Company Description

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.

It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.

The company was founded in 2015 and is headquartered in Markham, Canada.

Edesa Biotech, Inc.
Edesa Biotech logo
Country Canada
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Pardeep Nijhawan

Contact Details

Address:
100 Spy Court
Markham, ON L3R 5H6
Canada
Phone 289 800 9600
Website edesabiotech.com

Stock Details

Ticker Symbol EDSA
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001540159
CUSIP Number 27966L108
ISIN Number CA27966L3065
SIC Code 2834

Key Executives

Name Position
Dr. Pardeep Nijhawan FRCPC, M.D. Chief Executive Officer, Company Secretary and Director
Dr. Michael J. Brooks M.B.A., Ph.D. President
Stephen L. Lemieux BA, CPA, CA, CPA, MMPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 11, 2025 EFFECT Notice of Effectiveness
Mar 11, 2025 424B3 Prospectus
Mar 4, 2025 S-3 Registration statement under Securities Act of 1933
Mar 4, 2025 UPLOAD Filing
Feb 25, 2025 SCHEDULE 13G Filing
Feb 20, 2025 UPLOAD Filing
Feb 18, 2025 SCHEDULE 13D Filing
Feb 18, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13D/A Filing
Feb 14, 2025 D Notice of Exempt Offering of Securities